Citadel Advisors’s PAVmed PAVM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,947
Closed -$42.1K 14392
2025
Q1
$42.1K Buy
+1,947
New +$40.4K ﹤0.01% 12489
2023
Q4
Sell
-99
Closed -$13.1K 14971
2023
Q3
$13.1K Sell
99
-2
-2% -$310 ﹤0.01% 12936
2023
Q2
$18.5K Sell
101
-32
-24% -$6.4K ﹤0.01% 12790
2023
Q1
$22.3K Sell
133
-173
-57% -$36.4K ﹤0.01% 12991
2022
Q4
$66K Sell
306
-17
-5% -$6.42K ﹤0.01% 11781
2022
Q3
$125K Buy
323
+74
+30% +$41.9K ﹤0.01% 10896
2022
Q2
$105K Buy
249
+7
+3% +$3.38K ﹤0.01% 11369
2022
Q1
$143K Buy
242
+54
+29% +$40.1K ﹤0.01% 11909
2021
Q4
$209K Buy
188
+1
+0.5% +$2.17K ﹤0.01% 11762
2021
Q3
$719K Buy
187
+73
+64% +$230K ﹤0.01% 9001
2021
Q2
$327K Buy
114
+61
+115% +$144K ﹤0.01% 11057
2021
Q1
$105K Buy
+53
New +$79.7K ﹤0.01% 12433

Other funds holding PAVM

Citadel Advisors's PAVM Position: Q1 2023 in Review

Citadel Advisors sold out of PAVmed (PAVM) in Q1 2023, closing a stake of 56 shares — an estimated $11.8K sold.

Citadel Advisors first reported a position in PAVM in Q2 2019 and held it in 11 quarters. The position peaked at $3.95M in Q4 2021. 58 funds tracked by Wall St. Rank hold PAVM as of Q1 2023.

  • Citadel Advisors reported no remaining PAVmed position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 56 PAVmed shares in Q1 2023, an estimated $11.8K.
  • Citadel Advisors first reported a position in PAVmed in Q2 2019 and held it in 11 quarters.
  • Citadel Advisors's PAVmed position peaked at $3.95M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held PAVmed as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.